Xeris Biopharma officer proposes $262K share sale

The shares proposed for sale came from restricted stock units that vested between January 31, 2024 and January 31, 2025.

Available on EDGAR 11/05/2026 - 04:32 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. officer Kevin McCulloch gave notice of a proposed sale of 25,000 common shares, with an aggregate market value of $261,500, through Morgan Stanley Smith Barney LLC. The form lists November 5, 2026 as the approximate sale date.

It also lists four transactions under “10b5-1 Sales”: 15,000 shares for $153,487.50 on November 2, 2026; 15,000 shares for $141,120 on October 1, 2026; 25,000 shares for $250,000 on September 28, 2026; and 15,000 shares for $127,308.35 on September 1, 2026.

Key Figures

Proposed sale: 25,000 common shares Aggregate market value: $261,500 Approximate sale date: November 5, 2026 +5 more

8 metrics

Proposed sale 25,000 common shares Notice of sale by Kevin McCulloch

Aggregate market value $261,500 Proposed sale

Approximate sale date November 5, 2026 Date listed for the proposed sale

Shares outstanding 182,320,306 shares Number reported in the securities information

Prior sale 15,000 shares November 2, 2026; reported sale value $153,487.50

Prior sale 15,000 shares October 1, 2026; reported sale value $141,120

Prior sale 25,000 shares September 28, 2026; reported sale value $250,000

Prior sale 15,000 shares September 1, 2026; reported sale value $127,308.35

Key Terms

Restricted Stock Units, 10b5-1 Sales, Rule 144

3 terms

Restricted Stock Units financial

"Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for KEVIN MCCULLOCH"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many XERS shares did Kevin McCulloch propose to sell?

Kevin McCulloch gave notice of a proposed sale of 25,000 common shares, with an aggregate market value of $261,500. The form lists Morgan Stanley Smith Barney LLC as the broker and November 5, 2026 as the approximate sale date.

What XERS sales did Kevin McCulloch report for the prior three months?

Under the “10b5-1 Sales” heading, he reported sales of 15,000 shares for $153,487.50 on November 2, 2026; 15,000 shares for $141,120 on October 1, 2026; 25,000 shares for $250,000 on September 28, 2026; and 15,000 shares for $127,308.35 on September 1, 2026.

How were the XERS shares proposed for sale acquired?

The shares were acquired upon the vesting of restricted stock units during the period from January 31, 2024 through January 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002031695
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	XERIS BIOPHARMA HOLDINGS, INC.
SEC File Number	001-40880
Address of Issuer	1375 West Fulton Street, Suite 1300 Chicago ILLINOIS 60607
Phone	8444455704
Name of Person for Whose Account the Securities are To Be Sold	KEVIN MCCULLOCH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	261500.00	182320306	11/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2024	Restricted Stock Units	Issuer			25000	01/31/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KEVIN MCCULLOCH 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	11/02/2026	15000	153487.50
10b5-1 Sales for KEVIN MCCULLOCH 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	10/01/2026	15000	141120.00
10b5-1 Sales for KEVIN MCCULLOCH 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	09/28/2026	25000	250000.00
10b5-1 Sales for KEVIN MCCULLOCH 1375 West Fulton Street, Suite 1300 Chicago IL 60607	Common	09/01/2026	15000	127308.35

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/31/2024 through 01/31/2025.
Date of Notice	11/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kevin McCulloch
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)